睿知中国疾病研究地图
候选清单0

即将招募重症肌无力早期I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Clinical Study to Evaluate the Safety and Efficacy of GT802 Injection in the Treatment of Refractory Generalized Myasthenia Gravis

ClinicalTrials.gov 上登记的一项重症肌无力开放试验,由华中科技大学同济医学院附属同济医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方(推断)华中科技大学同济医学院附属同济医院Tongji Hospital武汉医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07917923,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 4

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(4 项)收起清单
  1. 18 岁 至 65 岁;性别:不限

    登记记录的入选字段

  2. 4. Any prior systemic therapy for the indication must have a washout period of at least 4 weeks or 5 half-lives, whichever is shorter, before the participant is scheduled to receive study treatment.

    入选标准第 4 条

    5. Toxicities attributable to prior treatment must have stabilized and recovered to Grade ≤1.

    入选标准第 5 条

    13. Received intravenous immunoglobulin, plasma exchange or immunoadsorption therapy within 4 weeks prior to study treatment.

    排除标准第 13 条

    14. Received B-cell targeted therapy within 1 month prior to study treatment.

    排除标准第 14 条

    15. Received tacrolimus, cyclosporine, azathioprine, mycophenolate mofetil, mycophenolic acid, methotrexate, etc., within 2 weeks prior to study treatment.

    排除标准第 15 条

    16. Received neonatal Fc receptor (FcRn) antagonist therapy within 2 weeks prior to study treatment.

    排除标准第 16 条

    17. Received complement inhibition therapy within 2 weeks prior to study treatment.

    排除标准第 17 条

    18. Received systemic glucocorticoids at a dose >10 mg/day prednisone equivalent within 7 days prior to study treatment.

    排除标准第 18 条

  3. 3. History of active malignancy or any malignancy within 5 years prior to screening.

    排除标准第 3 条

    4. Presence of any active or untreated thymoma, or history of thymic carcinoma or other early pseudotumors of thymic malignancy.

    排除标准第 4 条

    9. Positive result for any of the following tests: a) Positive human immunodeficiency virus (HIV) antibody; b) Positive hepatitis B surface antigen (HBsAg) and/or positive hepatitis B core antibody (HBcAb), with HBV-DNA above the lower limit of quantitation of the assay; c) Positive hepatitis C virus (HCV) antibody, with HCV-RNA above the lower limit of quantitation of the assay; d) Positive syphilis antibody (excluding false-positive results caused by underlying diseases).

    排除标准第 9 条

    11. Active tuberculosis prior to screening.

    排除标准第 11 条

  4. 8. Pregnancy requirements:

    入选标准第 8 条

    Agrees to refrain from breastfeeding during study participation until at least 1 year after infusion of GT802 Injection or until GT802 cells are no longer detectable by 2 consecutive flow cytometry assays, whichever occurs later.

    入选标准第 10 条

    Male participants with female partners and female participants of childbearing potential agree to use highly effective contraception (e.g., oral contraceptives, intrauterine device or condoms) starting at screening and continuing until at least 1 year after infusion of GT802 Injection or until GT802 cells are no longer detectable by 2 consecutive flow cytometry assays, whichever occurs later. Male participants must agree to use condoms during sexual contact with pregnant females or females of childbearing potential for at least 1 year after GT802 Injection infusion, even after successful vasectomy.

    入选标准第 11 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);日常活动能力;化验:血常规、肝肾功能;影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07917923,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. 1. The participant or their legally authorized representative voluntarily signs the written informed consent form and is willing and able to comply with the study procedures.
  2. 2. Aged 18-65 years (inclusive) at the time of informed consent, without gender restriction.
  3. 3. Expected survival > 12 weeks.
  4. 4. Any prior systemic therapy for the indication must have a washout period of at least 4 weeks or 5 half-lives, whichever is shorter, before the participant is scheduled to receive study treatment.
  5. 5. Toxicities attributable to prior treatment must have stabilized and recovered to Grade ≤1.
  6. 6. Refractory generalized myasthenia gravis, as defined in the protocol.
  7. 7. Screening laboratory results meet the criteria specified in the protocol.
  8. 8. Pregnancy requirements:
  9. At screening, serum beta human chorionic gonadotropin (β-hCG) pregnancy test is negative as confirmed by the investigator.
  10. Agrees to refrain from breastfeeding during study participation until at least 1 year after infusion of GT802 Injection or until GT802 cells are no longer detectable by 2 consecutive flow cytometry assays, whichever occurs later.
  11. Male participants with female partners and female participants of childbearing potential agree to use highly effective contraception (e.g., oral contraceptives, intrauterine device or condoms) starting at screening and continuing until at least 1 year after infusion of GT802 Injection or until GT802 cells are no longer detectable by 2 consecutive flow cytometry assays, whichever occurs later. Male participants must agree to use condoms during sexual contact with pregnant females or females of childbearing potential for at least 1 year after GT802 Injection infusion, even after successful vasectomy.

排除标准:Exclusion Criteria:

  1. 1. Contraindication or hypersensitivity to any component of the investigational product.
  2. 2. Presence of conditions specified in the protocol within 6 months prior to signing the informed consent form.[沈9.1]
  3. 3. History of active malignancy or any malignancy within 5 years prior to screening.
  4. 4. Presence of any active or untreated thymoma, or history of thymic carcinoma or other early pseudotumors of thymic malignancy.
  5. 5. Autoimmune diseases other than the study disease that require systemic glucocorticoids or immunosuppressants.
  6. 6. Requirement for long-term administration of medications affecting coagulation function.
  7. 7. Participants with clinically obvious bleeding symptoms or definite bleeding tendency within 6 months before screening.
  8. 8. Presence of severe underlying medical conditions at screening.
  9. 9. Positive result for any of the following tests: a) Positive human immunodeficiency virus (HIV) antibody; b) Positive hepatitis B surface antigen (HBsAg) and/or positive hepatitis B core antibody (HBcAb), with HBV-DNA above the lower limit of quantitation of the assay; c) Positive hepatitis C virus (HCV) antibody, with HCV-RNA above the lower limit of quantitation of the assay; d) Positive syphilis antibody (excluding false-positive results caused by underlying diseases).
  10. 10. Positive cytomegalovirus (CMV)-DNA and Epstein Barr virus (EBV)-DNA in peripheral blood.
  11. 11. Active tuberculosis prior to screening.
  12. 12. Received any other investigational medicinal product within 4 weeks before signing the informed consent form (ICF).
  13. 13. Received intravenous immunoglobulin, plasma exchange or immunoadsorption therapy within 4 weeks prior to study treatment.
  14. 14. Received B-cell targeted therapy within 1 month prior to study treatment.
  15. 15. Received tacrolimus, cyclosporine, azathioprine, mycophenolate mofetil, mycophenolic acid, methotrexate, etc., within 2 weeks prior to study treatment.
  16. 16. Received neonatal Fc receptor (FcRn) antagonist therapy within 2 weeks prior to study treatment.
  17. 17. Received complement inhibition therapy within 2 weeks prior to study treatment.
  18. 18. Received systemic glucocorticoids at a dose >10 mg/day prednisone equivalent within 7 days prior to study treatment.
  19. 19. Received live attenuated vaccines or mRNA vaccines within 8 weeks before enrollment, or inactivated vaccines within 4 weeks before enrollment.
  20. 20. Underwent major surgery within 8 weeks before screening, or planned to undergo surgery during the study period.
  21. 21. History of organ transplantation, splenectomy, allogeneic or autologous stem cell transplantation.
  22. 22. Presence of non-removable, clinically significant long-term indwelling catheters or drainage devices.
  23. 23. Uncontrolled large-volume serous cavity effusion despite treatment.
  24. 24. Prior receipt of CAR-T products targeting any antigen or other gene-edited cell biotherapies.
  25. 25. The investigator judges that any condition exists that would prevent the participant from completing the entire trial, confound the trial results, or make trial participation not in the participant's best interest.

引自 ClinicalTrials.gov, NCT07917923, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07917923,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07917923